PCI Pharma Services has made an investment in fully contained Xcelodose 600S technology at its UK-based center of excellence for contained manufacturing in Tredegar. This investment delivers another capability for the facility in the development and manufacturing of highly potent molecules. The pharmaceutical landscape continues to evolve with more and more products in development being deemed potent. As the biological activity and specificity of active pharmaceutical ingredients (API) increa...